Tyrosine kinase inhibitor, methyl 2,5-dihydromethylcinnimate, induces PML nuclear body formation and apoptosis in tumor cells

Experimental Cell Research

Volumn 313, Issue 13, 2007, Pages 2753-2765

  Komura, Naoyuki ^a   Asakawa, Mayako ^a   Umezawa, Kazuo ^a   Segawa, Kaoru ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

METHYL 2,5 DIHYDROMETHYLCINNIMATE; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; SUMO 1 PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS INCLUSION BODY; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN STABILITY; TUMOR CELL;

EID: 34547143196     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2007.03.032     Document Type: Article

References (55)

1. Stuurman N., de Graaf A., Floore A., Josso A., Humbel B., de Jong L., and van Driel R. A monoclonal antibody recognizing nuclear matrix-associated nuclear bodies. J. Cell Sci. 101 (1992) 773-784
2. Dyck J.A., Maul G.G., Miller Jr. W.H., Chen J.D., Kakizuka A., and Evans R.M. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 76 (1994) 333-343
3. Weis K., Rambaud S., Lavau C., Jansen J., Carvalho T., Carmo-Fonseca M., Lamond A., and Dejean A. Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell 76 (1994) 345-356
4. 3-induced PML or PML/retinoic acid receptor alpha degradation. J. Exp. Med. 193 (2001) 1361-1371
5. Muratani M., Gerlich D., Janicki S.M., Gebhard M., Eils R., and Spector D.L. Metabolic-energy-dependent movement of PML bodies within the mammalian cell nucleus. Nat. Cell Biol. 4 (2002) 106-110
6. Wiesmeijer K., Molenaar C., Bekeer I.M., Tanke H.J., and Dirks R.W. Mobile foci of Sp100 do not contain PML: PML bodies are immobile but PML and Sp100 proteins are not. J. Struct. Biol. 140 (2002) 180-188
7. Zhu J., Lallemand-Breitenbach V., and de The H. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene 20 (2001) 7257-7265
8. Zhu J., Chen Z., Lallemand-Breitenbach V., and de The H. How acute promyelocytic leukaemia revived arsenic. Nat. Rev., Cancer 2 (2002) 705-713
9. Li H., Leo C., Zhu J., Wu X., O'Neil J., Park E.J., and Chen J.D. Sequestration and inhibition of Daxx-mediated transcriptional repression by PML. Mol. Cell. Biol. 20 (2000) 1784-1796
10. Zhong S., Salomoni P., and Pandolfi P.P. The transcriptional role of PML and the nuclear body. Nat. Cell Biol. 2 (2000) E85-E90
11. Everett R.D. DNA viruses and viral proteins that interact with PML nuclear bodies. Oncogene 20 (2001) 7266-7273
12. Regad T., and Chelbi-Alix M.K. Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene 20 (2001) 7274-7286
13. Salomoni P., and Pandolfi P.P. The role of PML in tumor suppression. Cell 108 (2002) 165-170
14. Bischof O., Kim S.H., Irving J., Beresten S., Ellis N.A., and Campisi J. Regulation and localization of the Bloom syndrome protein in response to DNA damage. J. Cell Biol. 153 (2001) 367-380
15. Xu Z.X., Timanova-Atanasova A., Zhao R.X., and Chang K.S. PML colocalizes with and stabilizes the DNA damage response protein TopBPI. Mol. Cell. Biol. 23 (2003) 4247-4256
16. Ferbeyre G., de Stanchina E., Querido E., Baptiste N., Prives C., and Lowe S.W. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 14 (2000) 2015-2027
17. Pearson M., Carbone R., Sebastiani C., Cioce M., Fagioli M., Saito S., Higashimoto Y., Appella E., Minucci S., Pandolfi P.P., and Pelicci P.G. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406 (2000) 207-210
18. Hofmann T.G., Moller A., Sirma H., Zentgraf H., Taya Y., Droge W., Will H., and Schmitz M.L. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat. Cell Biol. 4 (2002) 1-10
19. D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y., Saito S., Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G., Fanciulli M., Appella E., and Soddu S. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell Biol. 4 (2002) 11-19
20. Duprez E., Saurin A.J., Desterro J.M., Lallemand-Breitenbach V., Howe K., Boddy M.N., Solomon E., de The H., Hay R.T., and Freemont P.S. SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. J. Cell Sci. 112 (1999) 381-393
21. Ishov A.M., Sotnikov A.G., Negorev D., Vladimirova O.V., Neff N., Kamitani T., Yeh E.T., Strauss III J.F., and Maul G.G. PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J. Cell Biol. 147 (1999) 221-234
22. Pearson M., Carbone R., Sebastiani C., Cioce M., Fagioli M., Saito S., Higashimoto Y., Appella E., Minucci S., Pandolfi P.P., and Pelicci P.G. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406 (2000) 207-210
23. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
24. Yu J., Zhang L., Hwang P.M., Kinzler K.W., and Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 7 (2001) 673-682
25. Nakano K., and Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7 (2001) 683-694
26. Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., Yamashita T., Tokino T., Taniguchi T., and Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288 (2000) 1053-1058
27. Koken M.H., Puvion-Dutilleul F., Guillemin M.C., Viron A., Linares-Cruz G., Stuurman N., de Jong L., Szostecki C., Calvo F., Chomienne C., Degos L., Puvion E., and de The H. The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J. 13 (1994) 1073-1083
28. de The H. Altered retinoic acid receptors. FASEB J. 10 (1996) 955-960
29. Kawasaki A., Matsumura I., Kataoka Y., Takigawa E., Nakajima K., and Kanakura Y. Opposing effects of PML and PML/RAR alpha on STAT3 activity. Blood 101 (2003) 3668-3673
30. Rego E.M., Wang Z.G., Peruzzi D., He L.Z., Cordon-Cardo C., and Pandolfi P.P. Role of promyelocytic leukemia (PML) protein in tumor suppression. J. Exp. Med. 193 (2001) 521-529
31. Grignani F., Fagioli M., Ferrucci P.F., Alcalay M., and Pelicci P.G. The molecular genetics of acute promyelocytic leukemia. Blood Rev. 7 (1993) 87-93
32. Zhong S., Muller S., Ronchetti S., Freemont P.S., Dejean A., and Pandolfi P.P. Role of SUMO-1-modified PML in nuclear body formation. Blood 95 (2000) 2748-2752
33. Kamitani T., Nguyen H.P., Kito K., Fukuda-Kamitani T., and Yeh E.T. Covalent modification of PML by the sentrin family of ubiquitin-like proteins. J. Biol. Chem. 273 (1998) 3117-3120
34. Johnson E.S. Protein modification by SUMO. Annu. Rev. Biochem. 73 (2004) 355-382
35. Umezawa K., Hori T., Tajima H., Imoto M., Isshiki K., and Takeuchi T. Inhibition of epidermal growth factor-induced DNA synthesis by tyrosine kinase inhibitors. FEBS Lett. 260 (1990) 198-200
36. Villunger A., Michalak E.M., Coultas L., Mullauer F., Bock G., Ausserlechner M.J., Adams J.M., and Strasser A. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302 (2003) 1036-1038
37. Jeffers J.R., Parganas E., Lee Y., Yang C., Wang J., Brennan J., MacLean K.H., Han J., Chittenden T., Ihle J.N., McKinnon P.J., Cleveland J.L., and Zambetti G.P. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 4 (2003) 321-328
38. Oda K., Arakawa H., Tanaka T., Matsuda K., Tanikawa C., Mori T., Nishimori H., Tamai K., Tokino T., Nakamura Y., and Taya Y. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102 (2000) 849-862
39. Fortin A., Cregan S.P., MacLaurin J.G., Kushwaha N., Hickman E.S., Thompson C.S., Hakim A., Albert P.R., Cecconi F., Helin K., Park D.S., and Slack R.S. APAF1 is a key transcriptional target for p53 in the regulation of neuronal cell death. J. Cell Biol. 155 (2001) 207-216
40. Fu C., Ahmed K., Ding H., Ding X., Lan J., Yang Z., Miao Y., Zhu Y., Shi Y., Zhu J., Huang H., and Yao X. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3. Oncogene 24 (2005) 5401-5413
41. Muller S., Matunis M.J., and Dejean A. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J. 17 (1998) 61-70
42. 3-induced PML or PML/retinoic acid receptor alpha degradation. J. Exp. Med. 193 (2001) 1361-1371
43. Everett R.D., Lomonte P., Sternsdorf T., van Driel R., and Orr A. Cell cycle regulation of PML modification and ND10 composition. J. Cell Sci. 112 (1999) 4581-4588
44. Umezawa H., Imoto M., Sawa T., Isshiki K., Matsuda N., Uchida T., Iinuma H., Hamada M., and Takeuchi T. Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3. J. Antibiot. (Tokyo) 39 (1986) 170-173
45. Imoto M., Umezawa K., Sawa T., Takeuchi T., and Umezawa H. In situ inhibition of tyrosine protein kinase by erbstatin. Biochem. Int. 15 (1987) 989-995
46. Umezawa K., Tanaka K., Hori T., Abe S., Sekizawa R., and Imoto M. Induction of morphological change by tyrosine kinase inhibitors in Rous sarcoma virus-transformed rat kidney cells. FEBS Lett. 279 (1991) 132-136
47. Yang S., Kuo C., Bisi J.E., and Kim M.K. PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat. Cell Biol. 4 (2002) 865-870
48. Wang Z.G., Ruggero D., Ronchetti S., Zhong S., Gaboli M., Rivi R., and Pandolfi P.P. PML is essential for multiple apoptotic pathways. Nat. Genet. 20 (1998) 266-272
49. Zhong S., Salomoni P., Ronchetti S., Guo A., Ruggero D., and Pandolfi P.P. Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis. J. Exp. Med. 191 (2000) 631-640
50. Shieh S.Y., Ikeda M., Taya Y., and Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91 (1997) 325-334
51. Unger T., Juven-Gershon T., Moallem E., Berger M., Vogt Sionov R., Lozano G., Oren M., and Haupt Y. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J. 18 (1999) 1805-1814
52. Prives C., and Hall P.A. The p53 pathway. J. Pathol. 187 (1999) 112-126
53. Woods D.B., and Vousden K.H. Regulation of p53 function. Exp. Cell Res. 264 (2001) 56-66
54. Giaccia A.J., and Kastan M.B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12 (1998) 2973-2983
55. Cohen M.H., Williams G.A., Sridhara R., Chen G., McGuinn Jr. W.D., Morse D., Abraham S., Rahman A., Liang C., Lostritto R., Baird A., and Pazdur R. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin. Cancer Res. 10 (2004) 1212-1218